{
  "validated_facts": [
    {
      "drug_name": "citalopram",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
      "span": "A total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in Level 1 of STAR*D. Treatment could last up to 14 weeks in each level.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 2876,
      "duration": "up to 14 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "bupropion",
      "condition_name": "major depressive disorder",
      "relation": "AUGMENTS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
      "span": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286). Treatment could last up to 14 weeks in each level.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 279,
      "duration": "up to 14 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "buspirone",
      "condition_name": "major depressive disorder",
      "relation": "AUGMENTS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
      "span": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286). Treatment could last up to 14 weeks in each level.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 286,
      "duration": "up to 14 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "sertraline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
      "span": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286). Treatment could last up to 14 weeks in each level.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 238,
      "duration": "up to 14 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "venlafaxine",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
      "span": "In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286). Treatment could last up to 14 weeks in each level.",
      "confidence": 1.0,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 250,
      "duration": "up to 14 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "citalopram",
      "condition_name": "depression",
      "relation": "IMPROVES",
      "outcome": "remission",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Intervention",
      "span": "The aim of citalopram treatment in Level 1 was to achieve symptom remission, which was defined as QIDS-C score â‰¤ 5. The protocol required a fully adequate dose of citalopram for a sufficient time to maximize the likelihood of achieving remission.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 2876,
      "duration": null,
      "dose": "20-60 mg/day",
      "p_value": null
    },
    {
      "drug_name": "citalopram",
      "condition_name": "depression",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": null,
      "side_effects": [
        "greater frequency, intensity, and burden of side effects",
        "more serious adverse events"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Tolerability and Side Effects in Level 1, by Anxious Versus Nonanxious Depression",
      "span": "Despite similar citalopram dosages in the two groups and the longer treatment exposure in the nonanxious depression group (Table 1), the anxious depression group had greater a frequency, intensity, and burden of side effects than the nonanxious depression group, as well as more serious adverse events (Table 4).",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "citalopram",
      "condition_name": "nonanxious depression",
      "relation": "ASSOCIATED_WITH_SE",
      "outcome": null,
      "side_effects": [
        "fewer serious adverse events"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Tolerability and Side Effects in Level 1, by Anxious Versus Nonanxious Depression",
      "span": "Despite similar citalopram dosages in the two groups and the longer treatment exposure in the nonanxious depression group (Table 1), the anxious depression group had greater a frequency, intensity, and burden of side effects than the nonanxious depression group, as well as more serious adverse events (Table 4).",
      "confidence": 0.8,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": null,
      "sample_size": null,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "sustained-release bupropion",
      "condition_name": "major depressive disorder",
      "relation": "AUGMENTS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Sample Description of Level 2 Study Participants",
      "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to continue taking citalopram and receive augmentation with sustained-release bupropion (at a dose of up to 400 mg per day; N=279).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 279,
      "duration": null,
      "dose": "up to 400 mg per day",
      "p_value": null
    },
    {
      "drug_name": "buspirone",
      "condition_name": "major depressive disorder",
      "relation": "AUGMENTS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Sample Description of Level 2 Study Participants",
      "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to continue taking citalopram and receive augmentation with buspirone (at a dose of up to 60 mg per day; N=286).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 286,
      "duration": null,
      "dose": "up to 60 mg per day",
      "p_value": null
    },
    {
      "drug_name": "sustained-release bupropion",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Sample Description of Level 2 Study Participants",
      "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to sustained-release bupropion (at a maximal daily dose of 400 mg; N=239).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 239,
      "duration": null,
      "dose": "maximal daily dose of 400 mg",
      "p_value": null
    },
    {
      "drug_name": "sertraline",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Sample Description of Level 2 Study Participants",
      "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to sertraline (at a maximal daily dose of 200 mg; N=238).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 238,
      "duration": null,
      "dose": "maximal daily dose of 200 mg",
      "p_value": null
    },
    {
      "drug_name": "extended-release venlafaxine",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Sample Description of Level 2 Study Participants",
      "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to extended-release venlafaxine (at a maximal daily dose of 375 mg; N=250).",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "RCT",
      "sample_size": 250,
      "duration": null,
      "dose": "maximal daily dose of 375 mg",
      "p_value": null
    },
    {
      "drug_name": "citalopram",
      "condition_name": "depression",
      "relation": "IMPROVES",
      "outcome": "remission",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "discussion",
      "span": "In Level 1 of STAR*D, patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression. Overall, they also took longer to remit.",
      "confidence": 0.9,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "STAR*D Level 1",
      "sample_size": 2876,
      "duration": null,
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "citalopram",
      "condition_name": "major depressive disorder",
      "relation": "TREATS",
      "outcome": "remission",
      "side_effects": [
        "worsening insomnia",
        "nervousness",
        "dryness of mouth",
        "constipation"
      ],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Patient Perspective",
      "span": "After 6 weeks of combined treatment with citalopram and a benzodiazepine, Ms. D reported a significant improvement in all her symptoms, and remission was achieved at the end of the 10th week of treatment.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "case report",
      "sample_size": null,
      "duration": "10 weeks",
      "dose": null,
      "p_value": null
    },
    {
      "drug_name": "benzodiazepine",
      "condition_name": "major depressive disorder",
      "relation": "AUGMENTS",
      "outcome": "improvement in insomnia and agitation",
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null,
      "source_id": "Psychiatry",
      "section": "Patient Perspective",
      "span": "A benzodiazepine was prescribed, which brought about a significant improvement in her insomnia and agitation.",
      "confidence": 0.7,
      "treatment_line": null,
      "patient_subgroup": null,
      "study_design": "case report",
      "sample_size": null,
      "duration": "10 weeks",
      "dose": null,
      "p_value": null
    }
  ],
  "total_facts": 16,
  "validation_summary": {
    "original_count": 16,
    "valid_count": 16,
    "invalid_count": 0,
    "warning_count": 0
  }
}